MA42523B1 - Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations - Google Patents

Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations

Info

Publication number
MA42523B1
MA42523B1 MA42523A MA42523A MA42523B1 MA 42523 B1 MA42523 B1 MA 42523B1 MA 42523 A MA42523 A MA 42523A MA 42523 A MA42523 A MA 42523A MA 42523 B1 MA42523 B1 MA 42523B1
Authority
MA
Morocco
Prior art keywords
psma
antibodies
bind
antigen
binding molecules
Prior art date
Application number
MA42523A
Other languages
English (en)
Other versions
MA42523A (fr
Inventor
Gavin Thurston
Eric Smith
Jessica R Kirshner
Ashique Rafique
Alison Crawford
Lauric Haber
Drew Dudgeon
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2016/044732 external-priority patent/WO2017023761A1/fr
Publication of MA42523A publication Critical patent/MA42523A/fr
Publication of MA42523B1 publication Critical patent/MA42523B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps qui se lient à l'antigène membranaire spécifique de la prostate (psma), des anticorps bispécifiques qui se lient à psma et à cd3, et des procédés pour les utiliser. Selon certains modes de réalisation, les anticorps de l'invention se lient au psma humain avec une affinité élevée et se lient à cd3 pour induire la prolifération de cellules t humaines. L'invention comprend des anticorps qui se lient à psma et à cd3 et induisent l'élimination à médiation par les cellules t de cellules tumorales exprimant le psma. Selon certains modes de réalisation, la présente invention concerne des molécules liant l'antigène bispécifiques comprenant un premier domaine liant l'antigène qui se lie spécifiquement au cd3 humain, et une seconde molécule liant l'antigène qui se lie spécifiquement au psma humain. Dans certains modes de réalisation, les molécules liant l'antigène bispécifiques selon la présente invention sont capables d'inhiber la croissance de tumeurs de la prostate exprimant le psma. Les anticorps et les molécules liant l'antigène bispécifiques de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblée positivement régulée ou induite est souhaitée et/ou thérapeutiquement bénéfique. Par exemple, les anticorps de l'invention sont utiles pour le traitement de divers cancers.
MA42523A 2015-07-31 2016-07-29 Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations MA42523B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199823P 2015-07-31 2015-07-31
PCT/US2016/044732 WO2017023761A1 (fr) 2015-07-31 2016-07-29 Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA42523A MA42523A (fr) 2018-06-06
MA42523B1 true MA42523B1 (fr) 2023-03-31

Family

ID=85793864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42523A MA42523B1 (fr) 2015-07-31 2016-07-29 Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations

Country Status (1)

Country Link
MA (1) MA42523B1 (fr)

Also Published As

Publication number Publication date
MA42523A (fr) 2018-06-06

Similar Documents

Publication Publication Date Title
MA42935B1 (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PH12020552116A1 (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
MA49043B1 (fr) Formulation stable d'anticorps
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA201691858A1 (ru) Композиции антител для лечения опухолей
EA201590613A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
MA39313B1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA38194A1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
MA29427B1 (fr) Antagonistes et leurs methodes d'utilisation
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA43717B1 (fr) Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MA42523B1 (fr) Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations
MA37998B2 (fr) Anticorps anti-cd3, molécules de liaison à un antigène bispécifiques qui se lient à cd3 et cd20, et leurs utilisations
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
EA202190314A1 (ru) Биспецифические анти-bcma x анти-cd3 антитела и способы их применения
EA202190089A1 (ru) Биспецифичные антитела анти-psma x анти-cd28 и их применения
MA50374B1 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA46277B1 (fr) Anticorps anti-muc16-cd3 bi specifiques et conjugues d'anticorps anti-muc16 avec des anticancereux
MA38501A1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation